Derouane F, Marcke C, Berlière M, Gerday A, Fellah L, Leconte I, et al. Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine [Review of predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine]. Cancers. 2022;14(16):3876. https://doi.org/10.3390/cancers14163876.

Article  CAS  PubMed  PubMed Central  Google Scholar 

ELSayed BB, Alksas A, Shehata M, Mahmoud A, Zaky M, Alghandour R, et al. Exploring neoadjuvant chemotherapy, predictive models, radiomic, and pathological markers in breast cancer: a comprehensive review [Review of exploring neoadjuvant chemotherapy, predictive models, radiomic, and pathological markers in breast cancer: a comprehensive review]. Cancers. 2023;15(21):5288. https://doi.org/10.3390/cancers15215288.

Article  PubMed  PubMed Central  Google Scholar 

Kučiauskas D, Dreižė N, Ger M, Kaupinis A, Žemaitis K, Stankevičius V, et al. Proteomic analysis of breast cancer resistance to the anticancer drug RH1 reveals the importance of cancer stem cells. Cancers. 2019;11(7):972. https://doi.org/10.3390/cancers11070972.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A, et al. Molecular mechanisms, biomarkers and emerging therapies for chemotherapy resistant TNBC [Review of Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC]. Int J Mol Sci. 2022;23(3):1665. https://doi.org/10.3390/ijms23031665.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JS, Yost SE, Yuan Y. Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges [Review of Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges]. Cancers. 2020;12(6):1404. https://doi.org/10.3390/cancers12061404.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma T, Hao X, Chen H, Zheng M, Chen X, Cai S-L, et al. Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy. Sci Rep. 2025. https://doi.org/10.1038/s41598-024-84785-3.

Article  PubMed  PubMed Central  Google Scholar 

Yin L, Duan J-J, Bian X-W, Yu S. Triple-negative breast cancer molecular subtyping and treatment progress [Review of Triple-negative breast cancer molecular subtyping and treatment progress]. Breast Cancer Res. 2020;22(1). BioMed Central. https://doi.org/10.1186/s13058-020-01296-5. 

Ende N, Nguyen AH, Jager A, Kok M, Debets R, Deurzen C. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review [Review of triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review]. Int J Mol Sci. 2023;24(3):2969. https://doi.org/10.3390/ijms24032969.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu H, Zhu J, Zhong Y, Geng R, Ji Y, Guan Q, et al. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. Ann Transl Med. 2021;9(5):410. https://doi.org/10.21037/atm-21-698.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kneubil MC, Goulart KOB, Brollo J, Coelho GP, Mandelli J, Orlandin BC, et al. Predictive value of DNA repair gene expression for response to neoadjuvant chemotherapy in breast cancer. Braz J Med Biol Res. 2022. https://doi.org/10.1590/1414-431x2021e11857.

Article  PubMed  PubMed Central  Google Scholar 

Steelman LS, Chappell WH, Akula SM, Abrams SL, Cocco L, Manzoli L, et al. Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling [Review of Therapeutic resistance in breast cancer cells can result from deregulated EGFR signaling]. Adv Biol Regul. 2020;78:100758. https://doi.org/10.1016/j.jbior.2020.100758.

Article  CAS  PubMed  Google Scholar 

Pavese F, Capoluongo E, Muratore M, Minucci A, Santonocito C, Fuso P, et al. BRCA mutation status in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: a pivotal role for treatment decision-making. Cancers. 2022;14(19):4571. https://doi.org/10.3390/cancers14194571.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Цыганов ММ, Ибрагимова МК, Garbukov ЕY, Bragina O, Karchevskaya AA, Usynin EA, et al. Determination of BRCAness phenotype in breast tumors for the appointment of neoadjuvant chemotherapy based on platinum and taxanes. Int J Mol Sci. 2022;24(1):207. https://doi.org/10.3390/ijms24010207.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao L, Niu Y. Triple negative breast cancer: special histological types and emerging therapeutic methods [Review of Triple negative breast cancer: special histological types and emerging therapeutic methods]. Cancer Biology Med. 2020;17(2):293. https://doi.org/10.20892/j.issn.2095-3941.2019.0465. Chinese Anti-Cancer Association.

Article  CAS  Google Scholar 

Hakeem A, El-Kersh DM, Hammam O, Elhosseiny A, Zaki AR, Kamel K, et al. Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K/Akt/mTOR pathway and cancer stem cells. Sci Rep. 2024. https://doi.org/10.1038/s41598-024-65508-0.

Article  PubMed  PubMed Central  Google Scholar 

Rascio F, Spadaccino F, Rocchetti MT, Castellano G, Stallone G, Netti GS, et al. The pathogenic role of PI3K/AKT pathway in cancer onset and drug resistance: an updated review [Review of The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review]. Cancers. 2021;13(16):3949. https://doi.org/10.3390/cancers13163949.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Panda VK, Mishra B, Mahapatra S, Swain B, Malhotra D, Saha S, et al. Molecular insights on signaling cascades in breast cancer: a comprehensive review [Review of Molecular Insights on Signaling Cascades in Breast Cancer: A Comprehensive Review]. Cancers. 2025;17(2):234. https://doi.org/10.3390/cancers17020234.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tzeng H-E, Yang L, Chen K, Wang Y, Liu Y-R, Pan S, Gaur S, Hu S, Yen Y. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor. Oncotarget. 2015;6(13):11061. https://doi.org/10.18632/oncotarget.3568.

Article  PubMed  PubMed Central  Google Scholar 

Tao L, Zhu F, Xu F, Chen Z, Jiang Y, Chen Y. Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs [Review of Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs]. Pharmacol Res. 2015;102:123. https://doi.org/10.1016/j.phrs.2015.09.019.

Article  CAS  PubMed  Google Scholar 

Won K, Spruck C. Triple‑negative breast cancer therapy: current and future perspectives (Review) [Review of Triple‑negative breast cancer therapy: Current and future perspectives (Review)]. Int J Oncol. 2020;57(6):1245. https://doi.org/10.3892/ijo.2020.5135.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yesilkanal AE, Yang D, Valdespino A, Tiwari P, Sabino AU, Nguyen LC, et al. Limited inhibition of multiple nodes in a driver network blocks metastasis. Elife. 2021. https://doi.org/10.7554/elife.59696.

Article  PubMed  PubMed Central  Google Scholar 

Saha T, Mondal J, Khiste S, Lusic H, Hu Z, Jayabalan R, Hodgetts KJ, Jang H, Sengupta S, Lee SE, Park Y, Lee LP, Goldman A. Nanotherapeutic approaches to overcome distinct drug resistance barriers in models of breast cancer. Nanophotonics. 2021;10(12):3063. https://doi.org/10.1515/nanoph-2021-0142.

Article  CAS  PubMed  Google Scholar 

Yang J, Farren MR, Ahn DH, Bekaii-Saab T, Lesinski GB. Signaling pathways as therapeutic targets in biliary tract cancer [Review of Signaling pathways as therapeutic targets in biliary tract cancer]. Expert Opin Ther Targets. 2017;21(5):485. https://doi.org/10.1080/14728222.2017.1306055.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koirala M, DiPaola M. Overcoming cancer resistance: strategies and modalities for effective treatment [Review of Overcoming Cancer Resistance: Strategies and Modalities for Effective Treatment]. Biomedicines. 2024;12(8):1801. https://doi.org/10.3390/biomedicines12081801.

Article  CAS  PubMed  PubMed Central